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Edited by Laszlo NagyAbstract Tumor necrosis factor-a (TNF-a) induces the tran-
scriptional activation of numerous genes involved in the inﬂam-
matory response. The recently identiﬁed protein TRUSS
was investigated for its role in TNF-a-induced activation of
c-Jun-NH2 terminal kinase (JNK) and transcription factor,
AP-1. Ectopic expression of TRUSS activated JNK and AP-1
in the absence and presence of TNF-a stimulation. The C-termi-
nal region of TRUSS interacted with TNF receptor-associated
factor-2 (TRAF2) and co-expression of dominant-inhibitory
TRAF2 with TRUSS inhibited AP-1 activation, suggesting that
TRUSS signaling occurs upstream of TRAF2. Further, a domi-
nant-inhibitory mutant of TRUSS inhibited TNF-a-induced AP-
1 activation. These ﬁndings suggest that TRUSS activates JNK
in a TRAF2-dependent fashion and is involved in TNF-a-induced
AP-1 activation via JNK kinases.
 2006 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Tumor necrosis factor-a (TNF-a) plays a key role in inﬂam-
mation and host defense through its ability to interact with tu-
mor necrosis factor receptor-1 (TNF-R1) and regulate, in part,
the activity of the transcription factor, AP-1 [1–3]. AP-1 isAbbreviations: TRUSS, TNF receptor-associated ubiquitous scaﬀold-
ing and signaling protein; TNF-a, tumor necrosis factor-a; TRADD,
TNF receptor-associated death domain protein; TRAF2, TNF recep-
tor-associated factor-2; MAPK, mitogen-activated protein kinase;
JNK, c-Jun NH2-terminal kinase; AP-1, transcription factor activator
protein-1
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the Fos, Jun, Maf and ATF families [4]. Exposure to TNF-a
induces the expression of several immediate early gene mem-
bers of the AP-1 family including c-Fos and c-Jun [5,6]. In
addition, TNF-a stimulates the phosphorylation and tran-
scriptional activation of c-Jun through the activation of c-
Jun NH2-terminal kinases (JNKs) [1,7,8]. The signaling events
that connect ligation of TNF-R1 to the activation of JNKs are
initiated by the ligand-dependent recruitment of TNF recep-
tor-associated death domain protein (TRADD) to the cyto-
plasmic domain of TNF-R1 [9]. TRADD in turn serves as
an adapter protein to mediate the recruitment of TNF recep-
tor-associated factor-2 (TRAF2) [10], an essential signaling
molecule in JNK activation by TNF-a [11,12].
The subsequent signaling events are less clear. Like other
mitogen-activated protein kinase (MAPK) signaling cascades,
the activation of JNKs require three kinase modules, namely a
MAPK kinase kinase (MAP3K), which phosphorylates and
activates a MAPK kinase (MAPKK). In turn, the MAPKK
phosphorylates conservedThr andTyr residues in the activation
loop of JNKs to stimulate their Ser/Thr kinase activity [13]. At
least 11 MAP3Ks have been identiﬁed that activate JNKs upon
over-expression [13]. Of these, MEKK1, apoptosis signal-regu-
lating kinase 1 (ASK1) and germinal center kinase (GCK) have
been implicated in JNK activation by TNF-a [14–16]. Each of
these MAP3Ks stimulate JNK activation through their ability
to phosphorylate and activate MKK4 and MKK7 [17,18].
MKK4 primarily phosphorylates Tyr182 while MKK7 phos-
phorylates Thr180 [18,19]. While both MKK4 and MKK7 are
activated by UV irradiation or osmotic stress, TNF-a primarily
activates MKK7 [18] and MKK7-deﬁcient mouse embryonic
ﬁbroblasts, but not MKK4-deﬁcient ﬁbroblasts, fail to activate
JNK in response to TNF-a [19]. These ﬁndings suggest that
MKK7 is suﬃcient to activate both the p46 JNK1 and p54
JNK2 isoforms [20] in response to TNF-a.
While much has been learned about the molecular mecha-
nisms of TNF-R1-induced signaling [21], questions still remain
about how the signaling complexes involved in JNK and AP-1
activation are assembled beyond TRAF2. We recently re-
ported the initial functional characterization of TRUSS, a no-
vel 91 kDa TNF-R1-interacting protein that serves as a
scaﬀolding protein for TRADD, TRAF2 and components of
the IKK complex [22]. Sequence analysis has revealed that
the C-terminal region, encompassing residues 440–797, is
highly enriched in Leu residues and contains multiple putative
dileucine and acidic cluster internalization motifs. In addition,blished by Elsevier B.V. All rights reserved.
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forming to either the (P/S/A/T)x(Q/E)E or SxxE consensus se-
quences of which four are located in the N-terminal region and
one in the extreme C-terminal. The purpose of this study was
to investigate the role of TRUSS in the activation of JNK and
AP-1 by TNF-a. Our ﬁndings show that: (i) ectopic expression
of TRUSS activates JNK and AP-1, (ii) dominant negative
TRAF2 abrogates AP-1 activation caused by TRUSS and
TRAF2 interacts with the C-terminal region of TRUSS and
(iii) a dominant-inhibitory mutant of TRUSS inhibits TNF-
a-induced activation of AP-1. We propose that TRUSS is in-
volved in the signaling pathway that connects TNF-R1 liga-
tion to the activation of JNK and AP-1 in a TRAF2-
dependent manner.2. Materials and methods
2.1. Materials
Recombinant mouse and human TNF-a were purchased from R&D
Systems, Minneapolis, MN. Rabbit anti-HA antibody (Y-11) and anti-
TRAF2 (N-19) antibodies were from Santa Cruz (Santa Cruz, CA)
and mouse anti-HA IP antibody (12CA5) was from Roche Diagnostics
(Indianapolis, IN). Anti-FLAG M2 (# F3165) monoclonal antibody
was from Sigma Chemical Company (St. Louis, MO). Lipofectamine
reagents were from Invitrogen (Carlsbad, CA) and Opti-MEM was
from Gibco (Rockville, MD). Plasmids were prepared using the endo-
toxin free DNA Maxi Kit from Qiagen (Valencia, CA).
2.2. Transfection procedures
NIH-3T3 and HEK293 cells were maintained and transfected as pre-
viously described [22,23]. Transfected cells were harvested 18 h post-
transfection unless otherwise stated.
2.3. Reporter gene assays
NIH-3T3 cells were co-transfected with 250 ng of AP-1/luciferase
construct and the indicated amounts of TRUSS or other constructs
as described above. The amount of DNA used for each condition
was kept constant by adding varying amounts of plasmid pcDNA3.1+.
Thirty nanograms of pCMV-b Gal was also incorporated into the
transfection mix to allow for standardization of transfection eﬃcien-
cies. At 18 h post-transfection (unless stated), cells were stimulated
with TNF-a for 4 h, lysed and luciferase and b-galactosidase expres-
sion determined using the luciferase assay system described previously
[22]. Unless stated otherwise, the cells were stimulated with TNF-a at
10 ng/ml. Results are expressed as fold activation of luciferase over ba-
sal levels. Each experiment was conducted a minimum of three times in
triplicate. Means ± S.D. of representative experiments are shown.2.4. Electrophoretic mobility shift assays
NIH-3T3 cells seeded at 2 · 106 cells/100 mm plate were transfected
with the appropriate amount of plasmid pHA.TRUSS or pcDNA3.1+,
incubated for 18 h, left unstimulated or stimulated with TNF-a (10 ng/
ml) for 30 min and nuclear extracts prepared as described [24]. Four
micrograms of nuclear protein were incubated with a [c-32P]-end la-
beled AP-1 probe (#E3201, Promega, Madison, WI) for 30 min in
binding buﬀer (10 mM Tris–HCl, pH 7.5, containing 50 mM NaCl,
0.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl2 and 4% (v/v) glycerol).
Cold competitor oligonucleotide was incorporated into the reactions
at a 20-fold excess for 30 min prior to electrophoresis as indicated. Pro-
tein:DNA complexes were resolved by electrophoresis through a 6%
acrylamide/TBE gel (Bio-Rad) and the gels were dried onto Whatmann
3MM paper and exposed to Hyperﬁlm MP (Amersham International,
Buckinghamshire, UK).Fig. 1. Ectopic expression of HA-tagged TRUSS in NIH-3T3 cells
activates JNK. NIH-3T3 cells cells were transfected with the indicated
amounts of pHA-TRUSS and the cells left unstimulated (Panel A) or
were exposed to TNF-a (10 ng/ml) for 10 min (Panel B). Lysates were
prepared and assayed for JNK activity using GST-c-Jun1–79
Sepharose (25 lg) as a substrate.2.5. In vitro kinase assays
Transfected cells were stimulated with TNF-a (10 ng/ml) unless sta-
ted otherwise, washed in HEPES/NaCl (50 mM HEPES, pH 7.2 con-
taining 150 mM NaCl), lysed in 1 ml of NP-40 lysis buﬀer (50 mM
Tris, pH 7.6, containing 150 mMNaCl, 1% (v/v) NP-40, 5 mM EDTA,1 mM PMSF, 20 lg/ml leupeptin, 10 lg/ml aprotinin, 1 mM NaF,
1 mM Na3VO4), centrifuged and subjected to JNK activation assays
as described [25]. Immune complex kinase assays were performed as
described [23] except HA-JNK was immunoprecipitated with anti-
HA and recombinant soluble GST-c-Jun1–79 was used as a substrate.
2.6. TRAF2 co-immunoprecipitation
HEK293 cells plated at 3 · 106 cells/6-well plate were co-transfected
with 2.0 lg HA-tagged TRUSS wt or deletion mutant construct with
1 lg TRAF2 construct. After 18 h, cells were lysed in TRAF2 lysis buf-
fer as described [26] and TRAF2 was immunoprecipitated overnight
with 2 lg/IP anti-TRAF2 antibody and 30 ll Protein G PLUS agarose
beads (Santa Cruz). Beads were washed three times with lysis buﬀer be-
fore immunoprecipitates were analyzed by SDS–PAGE and Western
blotting.
2.7. Data analysis
Each experiment was conducted a minimum of three times in tripli-
cate. Means ± S.D. of representative experiments are shown where
appropriate.3. Results and discussion
3.1. TRUSS activates the c-Jun NH2 terminal kinase
To investigate the role of TRUSS in JNK activation,
NIH-3T3 cells were transfected with increasing amounts of a
plasmid encoding HA-tagged TRUSS and the cell lysates were
assayed for JNK activity using GST-c-Jun1-79 as substrate
(Fig. 1A). Increasing levels of expression of TRUSS (lower pa-
nel) led to a concentration-dependent increase in JNK activity
(upper panel). In response to TNF-a, ectopic expression of
TRUSS in NIH-3T3 cells modestly augmented JNK activa-
tion. Since the transfection frequency of NIH-3T3 cells is only
25% but most of the cells are capable of undergoing JNK
activation by TNF-a, the eﬀect of TRUSS on TNF-a-induced
JNK activation is masked. To circumvent this limitation, we
investigated the eﬀect of TRUSS on TNF-a-induced JNK acti-
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of up to 80%) with a co-transfection approach using increasing
amounts of TRUSS and a ﬁxed amount of HA-tagged p46
JNK. Transfected JNK was then immunoprecipitated and as-
sayed for kinase activity towards soluble GST-c-Jun1–79. Fig. 2
shows that transfection of TRUSS led to a dose-dependent in-
crease in JNK activation in HEK293 cells. Further, JNK acti-
vation was more clearly augmented following stimulation with
TNF-a.
3.2. TRUSS activates AP-1 and potentiates AP-1 activation by
TNF-a
Next, we investigated the eﬀect of ectopically expressed
TRUSS on nuclear translocation of AP-1 by EMSA, and on
AP-1-activation using an AP-1-dependent luciferase reporter
gene assay [3]. EMSAs performed on nuclear extracts prepared
from pHA-TRUSS transfected NIH-3T3 cells demonstrate
that transfection of TRUSS increased nuclear translocation
of AP-1 in comparison to cells transfected with vector alone
(Fig. 3A). Stimulation with TNF-a resulted in a predicable
increase in AP-1 nuclear translocation in empty vector trans-
fected cells but because of the low transfection frequency of
NIH-3T3 cells, we did not see an augmentation in AP-1 trans-
location in the presence of transfected TRUSS. The speciﬁcity
of the complex for the AP-1 consensus oligonucleotide probe
was conﬁrmed by incorporating of a 20-fold excess of unla-
belled competitor AP-1 probe in the reaction mixture
(Fig. 3A).Fig. 2. Ectopic expression of TRUSS in HEK293 cells activates JNK
and potentiates JNK in response to TNF-a. Panel A. HEK293 cells
were co-transfected with the indicated amounts of untagged TRUSS
plus a constant amount of HA-JNK (0.5 lg). Total DNA transfected
was kept constant using pcDNA3.1. 18 h post-transfection, unstimu-
lated cells were lysed, and an immune complex kinase assay performed
on immunoprecipitated HA-JNK (upper panel). TRUSS and HA-JNK
expression were detected by Western blotting with anti-TRUSS C/N
and anti-HA antibodies, respectively (lower panel). Panel B. HEK293
cells transfected as in Panel A were stimulated with 20 ng/ml hTNF-a
for 15 min. JNK kinase activity and TRUSS and HA-JNK expression
were determined as in Panel A. Data are representative more than
three experiments.
Fig. 3. TRUSS activates transcription factor AP-1 in NIH-3T3 cells.
Panel A. NIH-3T3 cells were transfected with 1 lg pHA-TRUSS or
empty vector and exposed to TNF-a (10 ng/ml) or medium alone for
30 min and nuclear proteins extracts were prepared. Four micrograms
of nuclear proteins were incubated with a radiolabelled oligonucleotide
corresponding to the AP-1 consensus binding site and the pro-
tein:DNA complexes resolved using native polyacrylamide gel electo-
phoresis (upper panel). HA-TRUSS expression was detected by
Western blotting with anti-HA antibody (lower panel). Panel B.
NIH-3T3 cells were co-transfected with the indicated amounts of
pHA-TRUSS, AP-1-luciferase reporter gene construct and pCMV-b-
gal and the cells left unstimulated (white bars) or stimulated with TNF-
a (10 ng/ml; black bars) for 4 h. Lysates were prepared and assayed for
luciferase activity (upper panel). HA-TRUSS expression detected by
Western blotting with anti-HA antibody (lower panel).To again overcome the limitation of transfection frequency,
we also investigated the eﬀect of TRUSS on the transcriptional
activation of AP-1 in a reporter gene assay. NIH-3T3 cells were
co-transfected with increasing amounts of pHA-TRUSS and a
ﬁxed amount of the AP-1/luciferase reporter construct. As
shown in Fig. 3B (upper panel), transfection of pHA-TRUSS
alone activated AP-1 in a dose-dependent manner that peaked
following transfection of 500 ng of plasmid. In contrast to the
eﬀect of TRUSS on JNK activation, transfection with higher
amounts of pHA-TRUSS led to reduced AP-1 activation. Stim-
ulation of TRUSS-transfected cells with TNF-a resulted in an
augmentation in AP-1 activation compared to that seen in
either the absence of transfected TRUSS or in the absence of
TNF-a stimulation (Fig. 3B, upper panel). Maximal levels of
TNF-a-dependent AP-1 activation were also seen following
transfection with 500 ng of plasmid. Transfection with greater
than 500 ng of pHA-TRUSS also resulted in a progressive de-
cline in AP-1 activation in the presence of TNF-a. Though
the mechanism underlying the reduced activation at higher
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vation of other signaling mechanisms required for full AP-1
activation, e.g. Fos induction or p38 activation. Alternatively,
TRUSS may exhibit suppressive activity on AP-1 activation,
but not JNK activation, at higher expression levels. Interest-
ingly, although TRUSS is ubiquitously expressed, we have ob-
served considerable variation in the level of expression in
diﬀerent cell lines and organs [27]. The level of TRUSS expres-
sion was conﬁrmed by immunoblotting of whole cell lysates
with anti-HA antibody (Fig. 3B, lower panel). Collectively,
these ﬁndings indicate that ectopic expression of TRUSS stim-
ulates (i) the nuclear translocation of the AP-1 transcriptional
complex and (ii) the activation of AP-1-dependent gene
transcription. Further, (iii) expression of TRUSS augments
TNF-a-induced AP-1-dependent reporter gene activation in
NIH-3T3 cells.
3.3. TNF-R1 is required for the TRUSS-mediated potentiation
of AP-1 activity
TNF-a interacts with both TNF-R1 and TNF-R2, though
most responses to soluble TNF-a are signaled by ligation of
TNF-R1 [25,28,29]. Previous studies have demonstrated that
human TNF-a interacts with mouse TNF-R1, but not with
TNF-R2 [30]. Therefore, to determine which receptor is in-
volved in the potentiation of TNF-a-dependent AP-1 activa-
tion in the presence of TRUSS we investigated the eﬀects of
human and mouse TNF-a on AP-1-dependent reporter gene
activity. Incubation of empty vector transfected cells with both
human and mouse TNF-a stimulated AP-1-dependent lucifer-
ase activity (Fig. 4). These observations are in good agreement
with previous ﬁndings and are consistent with the interpreta-
tion that TNF-R2 participates in responses to mouse TNF-a,
but not human TNF-a [31]. Further, the ﬁnding that human
TNF-a augments AP-1 activation following TRUSS expres-
sion indicates that TRUSS augments TNF-R1 signaling. This
conclusion is also consistent with the ﬁnding that TRUSS does
not interact with TNF-R2 (J.L. Terry and D.W.H. Riches,
unpublished observations).Fig. 4. TRUSS potentiates the TNF-R1-induced activation of AP-1.
NIH-3T3 cells were co-transfected with 0.5 lg of pHA-TRUSS or
empty vector together with the AP-1-luciferase reporter gene construct
and pCMV-b-gal. The cells were left unstimulated (white bars) or were
stimulated with mouse TNF-a (10 ng/ml, black bars) or human TNF-a
(10 ng/ml, stippled bars) for 4 h. Lysates were prepared and assayed
for luciferase activity (upper panel). HA-TRUSS expression levels were
detected by Western blotting with anti-HA antibody (lower panel).3.4. TRUSS activation by AP-1 is dependent on TRAF2
While forming a complex with TRADD and the cytoplasmic
domain of TNF-R1, TRAF2 has been shown to interact with
several upstream kinases involved in JNK activation including
GCK and ASK1 [14,15]. To determine if the eﬀect of TRUSS
is upstream or downstream of TRAF2, we investigated the ef-
fect of dominant negative TRAF2 (TRAF287–501) on TRUSS-
dependent activation of AP-1. p-HA-TRUSS or empty vector
were co-expressed with TRAF287-501 in NIH3T3 cells and 36 h
after transfection, the cells were incubated in medium alone or
were stimulated with TNF-a for 4 h (as a positive control). The
cell lysates were then assayed for AP-1 reporter gene expres-
sion. Fig. 5 shows that ectoptic expression of TRUSS in-
creased luciferase activity in the absence of TRAF287–501
compared to empty vector. However, the increase in luciferase
activity caused by TRUSS was completely inhibited in the
presence of TRAF287–501. As expected, TRAF287–501 inhibited
AP-1 activation in both the presence and absence of TNF-a
(Fig. 5). Western blotting (Fig. 5, lower panels) for HA-tagged
TRUSS and FLAG-tagged TRAF287–501 conﬁrmed that
equivalent amounts of each protein were expressed under each
condition. These observations suggest that that activation of
AP-1 by ectopically expressed TRUSS is dependent on TRAF2
signaling and that TRAF2 is located downstream of TRUSS in
the pathway leading to the activation of AP-1.
Previous studies [27] have shown that TRUSS contains 5
consensus TRAF2-binding motifs and both proteins form
a heteromeric complex when ectopically expressed. To fur-
ther understand the mechanism of TRAF2 involvement in
TRUSS-induced signaling, we mapped the location of the
TRAF2-binding region of TRUSS by co-expressing a series
of TRUSS deletion mutant together with TRAF2 in
HEK293 cells. We then immunoprecipitated TRAF2 from cellFig. 5. TRAF2 is involved in the TRUSS-mediated activation of AP-
1. NIH-3T3 cells were co-transfected with the indicated combinations
of pHA-TRUSS (100 ng), pFLAG.TRAF287-501 (3 lg), AP-1/lucif-
erase reporter construct and pCMV-b-gal. Thirty-six hours after
transfection, the cells were left unstimulated (white bars) or were
stimulated with mouse TNF-a (10 ng/ml, black bars) and prepared
lysates assayed for luciferase activity (upper panel). HA-TRUSS and
FLAG.TRAF287-501 expression was detected by Western blotting
with anti-HA antibody and anti-FLAG antibody, respectively (lower
panel).
Fig. 7. Inhibition of TNF-a-induced JNK activation by TRUSS
deletion mutants. NIH-3T3 cells were co-transfected with 3 lg of the
indicated pHA-TRUSS deletion mutants together with AP-1-luciferase
reporter gene construct and of pCMV-b-gal and the cells left
unstimulated (white bars) or were stimulated with TNF-a (10 ng/ml,
black bars) for 4 h. Lysates were prepared and assayed for luciferase
activity (upper panel). HA-TRUSS deletion mutants were also detected
by Western blotting with anti-HA antibody. Arrowheads indicate the
position of the TRUSS and the deletion mutants.
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Fig. 6 shows that while full-length TRUSS was co-immuno-
precipated with TRAF2, deletion mutants lacking parts of
the C-terminal region (TRUSS1–723 and TRUSS1–440 and
TRUSS193–593) resulted in a loss of TRAF2 binding. Further,
TRUSS440–797 and TRUSS593–797 were found to be suﬃcient
for TRAF2 binding. These ﬁnding suggest that the interaction
between TRUSS and TRAF2 is mediated by the extreme
C-terminus encompassed by residues 724–797.
3.5. TRUSS is involved in TNF-induced AP-1 activation
Finally, we used a deletion mutagenesis approach to investi-
gate the possible role of TRUSS in the TNF-R1-dependent
activation of AP-1. Three micrograms of each deletion mutant
construct shown in Fig. 7 were co-transfected into NIH-3T3
cells along with the AP-1 luciferase reporter construct, then
incubated in medium alone or stimulated with TNF-a
(10 ng/ml) for 4 h. Many of the constructs exhibited some
inhibitory activity consistent with the notion that TRUSS
may play a role as a scaﬀolding protein that interacts with mul-
tiple signaling proteins, including TRAF2. Constructs with C-
terminal deletions, such as TRUSS1–593 and TRUSS1–440, were
found to inhibit the TNF-a-induced increase in AP-1 reporter
gene expression. Expression of a deletion mutant lacking the
entire N-terminal region of TRUSS (TRUSS441–797) also inhib-
ited TNF-a-stimulated AP-1 activation, though a deletion mu-
tant lacking only the ﬁrst 195 N-terminal amino acids
(TRUSS196–797) was less eﬀective in blocking AP-1 activation.
Previous studies have shown that the N-terminal region of
TRUSS (encompassed by residues 1–440) may contain a site
capable of interacting with TNF-R1, though binding was abol-
ished with mutants encompassing residues 1–196 or 196–440
[22].Fig. 6. TRUSS interacts with TRAF2 via a C-terminal region. Panel
A. Full length TRUSS cartoon. Striped bars: consensus TRAF2
binding sites, Dark gray bars: dileucine motifs. Panel B. HEK293 cells
were co-transfected with HA-TRUSS mutants and TRAF2. Cell
lysates were immunoprecipitated with anti-TRAF2 or non-immune
IgG (n.i. IgG) as a control. Co-immunoprecipitated proteins were
blotted with anti-HA and anti-TRAF2. Blots are representative of at
least 3 experiments per construct.A comparison of Figs. 6 and 7 yields some inconsistences be-
tween the ability of a deletion mutant to bind TRAF2 and its
ability to activate AP-1. For example, TRUSS441–797 bound
TRAF2 but inhibited AP-1 activation, while TRUSS1–192 did
not bind TRAF2 yet augmented AP-1 activation. An interpre-
tation of these diﬀerences is complicated since the regions of
TRUSS responsible for binding to other TNF-R1 signaling
proteins, such as TRADD, have not yet been mapped. TRUSS
has also been observed to interact with itself (J.L. Terry and
D.W.H. Riches, unpublished observations). Thus, the ectopi-
cally expressed truncated proteins may interact with some,
but not all, endogenous signaling proteins. Consequently, this
may cause the assembly of signaling complexes that mimics the
TNF-R1 signal. Alternatively, the deletion mutants may cause
sequestration of molecules required for receptor-dependent
signaling.
The deleted C-terminal region of TRUSS is rich in putative
dileucine internalization motifs. Previous studies by Schutze
et al. [32] have provided evidence to suggest that the activation
of JNK by TNF-a is dependent on the internalization of TNF-
R1. Thus, over-expression of a deletion mutant lacking the C-
terminal (as in TRUSS1–593 and TRUSS1–440) may somehow
inhibit TNF-R1 internalization, while preserving functions of
the N-terminal region. Alternatively, deletion of this region
may prevent interaction with TNF-R1, or the recruitment of
signaling molecules, including TRAF2, to this region of
TRUSS. Also, as noted above, it is plausible that the N-termi-
nal and C-terminal regions of TRUSS interact with diﬀerent
components of the TNF-R1-stimulated signaling pathway
leading to JNK and AP-1 activation, an hypothesis that is con-
sistent with the observed pattern of inhibition of TNF-a-stim-
ulated AP-1 activation by mutants lacking either of these
regions.
In summary, the ﬁndings of the present study deﬁne a novel
role for the TNF-R1-associated protein, TRUSS, in the
4596 S.M. Soond et al. / FEBS Letters 580 (2006) 4591–4596activation of JNK and AP-1. Since TRUSS also interacts with
TRAF2, TRUSS may play an important role in JNK activa-
tion by connecting events initiated by the clustering of the
cytoplasmic domain of TNF-R1 to the activation of down-
stream MAP3Ks including MEKK1, ASK1 and/or GCK
[14,16,28,33]. Future studies directed at the characterization
of TRUSS-deﬁcient mice should provide further insights into
the function of TRUSS in TNF-a-induced JNK and AP-1 acti-
vation.
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